COMP <GO>
PLYX vs NTHI // NET PROFIT MARGIN
Polaryx Therapeutics Inc. (NASDAQ) VS. NeOnc Technologies Holdings Inc. (NASDAQ) • 15-METRIC TALLY: PLYX 2
— NTHI 2
■ METRIC PARITY
LAST: $1.75 (-5.91%) • MKT CAP: $92.7M
net-margins
—
LAST: $3.26 (+4.49%) • MKT CAP: $92.9M
net-margins
-60.00%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (PLYX VS. NTHI)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | PLYX | NTHI | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -35.00% | 0.00 | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -4.25% | -21.93% | +17.68 | PLYX | /fcf-yield <GO> |
| Operating Margin | — | -60.00% | — | TIE | /operating-margins <GO> |
| Net Profit Margin ACTIVE | — | -60.00% | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | -51.80% | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 3/9 | 1/9 | +2.00 | PLYX | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 31.5 | 50.6 | -19.12 | NTHI | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $92.7M | $92.9M | -$156.7K | NTHI | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | PLYX REV | NTHI REV | PLYX GROSS % | NTHI GROSS % | PLYX FCF | NTHI FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $40.0K | — | — | -$3.9M | -$20.4M |
| FY 2024 | $0 | $83.0K | — | — | -$2.6M | -$4.2M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
PLYX // BETA —
NTHI // BETA —